在肥胖症中调节矩阵金属蛋白酶活性:减肥手术和GLP-1/GIP基础药物治疗的比较效果
Konrad Wiśniewski1, Barbara Choromańska1, Mateusz Maciejczyk2
11st Department of General and Endocrine Surgery, Medical University of Bialystok, 24a M. Sklodowskiej-Curie Street, 15-276 Bialystok, Poland.
Journal of clinical medicine
|November 13, 2025
概括
腹腔外科手术有效降低矩阵金属蛋白酶 (MMP) 并改善肥胖的代谢健康. 虽然一些药物有助于减肥,但它们对MMP的直接影响需要进一步调查.
科学领域:
- 代谢性疾病研究研究.
- 肥胖和炎症研究的研究.
- 细胞外矩阵 (ECM) 改造
背景情况:
- 肥胖症涉及慢性炎症,ECM功能障碍和代谢问题.
- 矩阵金属蛋白酶 (MMPs),特别是MMP-2和MMP-9,对于与肥胖相关的ECM重塑和炎症至关重要.
研究的目的:
- 审查和讨论减肥手术和药物治疗 (GLP-1,GLP-1/GIP激动剂) 对MMP活性和肥胖的代谢结果的影响.
- 综合当前关于ECM重塑和炎症调节的证据.
主要方法:
- 来自PubMed,Scopus和Web of Science (2015-2024) 的文献叙事审查.
- 专注于检查MMP,炎症和代谢参数在肥胖治疗中的研究.
主要成果:
- 腹部手术显著降低MMP-9并使MMP-2活动正常化,改善ECM完整性,炎症和胰岛素敏感性.
- 药理疗法促进体重减轻和血糖控制,但直接的MMP影响不太了解.
结论:
- 减肥手术在管理与肥胖相关的MMP失调和相关的代谢并发症方面非常有效.
- 需要进一步的研究来阐明现代肥胖药物治疗对ECM重塑的机械效应.
相关概念视频
Glucagon-like Receptor Agonists
828
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
828
Dipeptidyl Peptidase 4 Inhibitors
570
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
570
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution
230
Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
230
Oral Hypoglycemic Agents: Biguanides and Glitazones
568
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
568
Regulation of Food Intake
2.3K
Short-term regulation of food intake primarily involves neural signals from the gastrointestinal (GI) tract, blood nutrient levels, and GI tract hormones. Communication between the gut and brain via vagal nerve fibers plays a significant role in evaluating the contents of the gut. Clinical studies have shown that protein ingestion produces a more prolonged response in these nerve fibers compared to an equivalent amount of glucose. Additionally, the activation of stretch receptors caused by GI...
2.3K
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
511
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
511


